Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov ID: NCT02070965

Public ClinicalTrials.gov record NCT02070965. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Parallel Group Open-Label Multicenter Study to Assess the Potential for Adrenal Supp and Syst Drug Abs Following Multi Dosing With DFD-01 (Betamethasone Dipropionate) Spray 0.05% in Adol Subjects With Mod to Sev Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.

Study identification

NCT ID
NCT02070965
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Primus Pharmaceuticals
Industry
Enrollment
75 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2013
Primary completion
Sep 30, 2014
Completion
Sep 30, 2014
Last update posted
Mar 6, 2024

2014

United States locations

U.S. sites
12
U.S. states
7
U.S. cities
11
Facility City State ZIP Site status
California Dermatology and Clinical Research Institute Encinitas California 92024
Encino Research Center T. Joseph Raoof MD, Inc. Encino California 91436
Redwood Dermatology Research Santa Rosa California 95403
Bettencourt Skin Center Henderson Nevada 89074
Academic Dermatology Associates Albuquerque New Mexico 87106
Dermatology Consulting Services High Point North Carolina 27262
Paddington Testing Company, Inc. Philadelphia Pennsylvania 19101
Tennessee Clinical Research Center Nashville Tennessee 37215
DermResearch, Inc. Austin Texas 78759
Center for Clinical Studies, LTD. LLP Houston Texas 77004
The University of Texas Health Science Center at Houston Houston Texas 77030
Suzanne Bruce and Associates, PA The Center for Skin Research Katy/Cinco Ranch Katy Texas 77494

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02070965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 6, 2024 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02070965 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →